Scholar Rock to develop cancer immunotherapy product SRK-181

Scholar Rock announced that it has selected SRK-181, a highly specific inhibitor of TGFbeta1 activation, as the first product candidate in its TGFbeta1 cancer immunotherapy program based on the strength of its preclinical data and human translational insights. Scholar Rock has initiated manufacturing and is progressing preclinical development efforts with plans to initiate a Phase 1 trial in patients with solid tumors in mid- 2020. SRK-181 is a fully human antibody designed to bind to, and prevent the activation of, latent TGFbeta1 with high affinity and high selectivity, as evidenced by minimal or no binding to latent TGFbeta2 and latent TGFbeta3 isoforms. Several important factors led to the decision to advance SRK-181 as a clinical development product candidate for the treatment of tumors resistant to checkpoint blockade therapies, such as anti-PD1 antibodies.
https://thefly.com/landingPageNews.php?id=2878183